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Abstract
Age-related macular degeneration (AMD) is a common, progressive multifactorial vision-
threatening disease and many genetic and environmental risk factors have been identified.
The risk of AMD is influenced by lifestyle and diet, which may be reflected by an altered met-
abolic profile. Therefore, measurements of metabolites could identify biomarkers for AMD,
and could aid in identifying high-risk individuals. Hypothesis-free technologies such as meta-
bolomics have a great potential to uncover biomarkers or pathways that contribute to dis-
ease pathophysiology. To date, only a limited number of metabolomic studies have been
performed in AMD. Here, we aim to contribute to the discovery of novel biomarkers and met-
abolic pathways for AMD using a targeted metabolomics approach of 188 metabolites. This
study focuses on non-advanced AMD, since there is a need for biomarkers for the early
stages of disease before severe visual loss has occurred. Targeted metabolomics was per-
formed in 72 patients with early or intermediate AMD and 72 control individuals, and metab-
olites predictive for AMD were identified by a sparse partial least squares discriminant
analysis. In our cohort, we identified four metabolite variables that were most predictive for
early and intermediate stages of AMD. Increased glutamine and phosphatidylcholine diacyl
C28:1 levels were detected in non-advanced AMD cases compared to controls, while the
rate of glutaminolysis and the glutamine to glutamate ratio were reduced in non-advanced
AMD. The association of glutamine with non-advanced AMD corroborates a recent report
demonstrating an elevated glutamine level in early AMD using a different metabolomics
technique. In conclusion, this study indicates that metabolomics is a suitable method for
the discovery of biomarker candidates for AMD. In the future, larger metabolomics studies
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Introduction
Age-related macular degeneration (AMD) is a common vision-threatening disease affecting
the elderly.[1–3] Visual loss in AMD occurs as a result of progressive degenerative events at
the centre of the retina, known as the macula. Early AMD is characterized by the accumulation
of waste products (drusen) in the macula. Usually, patients experience no or only mild com-
plaints at this stage. As AMD progresses, visual loss occurs and two advanced subtypes of
AMD are distinguished: geographic atrophy and choroidal neovascularization, also referred
to as wet AMD. Targeting vascular endothelial growth factor, which is central to the disease
process of wet AMD, has proven to be a highly effective treatment.[4] However, for the early,
intermediate and atrophic stages of AMD, constituting over 80% of AMD patients, no effective
treatment exists.
Many environmental and genetic risk factors for AMD have been discovered, including
age, smoking, dietary factors (plasma lipids and anti-oxidant levels) and both common and
rare genetic variants.[3, 5–9] However, not all individuals with a high genetic risk develop
AMD, while some low-risk individuals do develop AMD. Potentially, the disease risk in these
AMD patients could be influenced by lifestyle and diet, which may be reflected by their meta-
bolic profile. It has been described that metabolite levels can be influenced by many factors,
including age, body-mass index (BMI) and nutrition,[10] factors that are also associated with
AMD. Therefore, measurements of metabolites could identify biomarkers for AMD, which
could aid in identifying high-risk individuals.
Metabolomics is an hypothesis-free approach that enables simultaneous analysis of large
numbers of metabolites, and has the potential to uncover physiological pathways that differ
between patients and controls.[11] To date, only a limited number of metabolomic studies
have been performed in AMD.[12–17] Two small case-control studies involving a total of 45
and 40 individuals, respectively, showed that individual metabolites and metabolic pathways
relevant for AMD pathogenesis can be identified using metabolomics.[13, 15] Another larger
study in 396 individuals concluded that, although metabolite changes related to AMD are of
low magnitude, they seem to be specific to AMD and further studies are warranted.[12] More
recently, a study in 120 individuals indicated that the most significant metabolites belong to
the glycerophospholipid pathway.[16]
Here, we aim to contribute to the discovery of novel biomarkers for AMD and uncover
clinically relevant metabolic pathways using a targeted metabolomics approach. Ideally, future
AMD treatment should be initiated in early stages of the disease to prevent progression to
advanced AMD with accompanying visual loss. To identify biomarkers for early stages of the
disease, this study focuses on non-advanced AMD.
Materials and methods
Study design and study population
Individuals were selected from the European Genetic Database (EUGENDA), a large multi-
center database for clinical and molecular analysis of AMD. Disease status was determined
based on classification of color fundus photographs, and if available spectral domain optical
coherence tomograms and fluorescein angiography by certified graders according to the
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Cologne Image Reading Center and Laboratory (CIRCL) classification protocol as described
previously.[18] In this study, we included cases with non-advanced AMD defined as presence
of at least 10 small drusen (<63μm) and pigmentary changes in at least one eye, and absence
of central geographic atrophy or choroidal neovascularization in both eyes. Individuals having
only pigmentary changes, less than 10 small drusen or without macular abnormalities were
classified as control individuals.
Individuals were matched for age, sex, smoking status, body mass index (BMI), number or
risk alleles of two prominent common genetic variants in CFH (p.Y402H; rs1061170) and
ARMS2 (p.A69S; rs10490924), and complement activation levels (measured as C3d/C3 ratio
[19]) to minimize potential confounding effects. Interviewer-assisted questionnaires provided
information on lifestyle, dietary habits and other environmental factors. For metabolomic
analyses in this study, 72 AMD cases and 72 controls were selected (total n = 144).
This study was approved by the local ethical committees at both sites of patient recruitment,
the Radboud university medical center and the University Hospital of Cologne, and was per-
formed in accordance with the tenets of the Declaration of Helsinki. Written informed consent
was provided by all individuals.
Serum collection and genotyping
Venous blood samples were collected from all individuals in a non-fasting state at time of
enrolment in EUGENDA. Serum was obtained using standardized coagulation and centrifuga-
tion procedures, and subsequently stored at -80˚C within one hour after collection until
analysis.
Genomic DNA was extracted from peripheral blood leukocytes, and genotyping of single
nucleotide polymorphisms (SNPs) in the CFH (rs1061170) and ARMS2 (rs10490924) genes
was performed using competitive allele-specific PCR assays (KASPar SNP Genotyping System,
KBiosciences).
Targeted metabolomics
Targeted identification and quantification of 188 metabolites (S1 Table) was achieved by exe-
cuting the mass spectrometric acquisition methods as provided by the AbsoluteIDQ p180 kit
(Biocrates Life Sciences, Innsbruck, Austria) with some modifications. In brief, after thawing
serum samples were centrifuged at 2750xg at 4˚C for 5 minutes. Subsequently, 10 μL of each
sample, quality controls, calibrators and zero samples were pipeted on the upper filter inlays of
the AbsoluteIDQ multiwell plate, which already contained the proprietary mixture of internal
standards. After drying, each filter inlay was incubated with 50 μL of 5% (v/v) phenylisothio-
cyanate in a solvent solution consisting of ethanol, water and pyridine (1:1:1) at room tempera-
ture for 20 minutes. The final extraction of the metabolites was performed for each well with
300 μL of methanol containing 5 mM ammonium acetate using a positive pressure device
(Waters, Eschborn, Germany). Instead of using a conventional HPLC-MS system the analyses
were performed on an Eksigent 200 microLC chromatography system (ABSciex, Darmstadt,
Germany) coupled to a 6500 QTRAP (ABSciex, Darmstadt, Germany). To detect amino acids
and biogenic amines, 50 μL of the metabolite extract were diluted in 350 μL of 50% methanol.
Chromatography was performed using two running solvents (A: water, 0.2% formic acid; B:
acetonitrile, 0.2% formic acid). Two μL of the diluted metabolite extracts were resolved on an
Acquity UPLC BEH C18, 1.0 x 50 mm (120 A) reverse phase column (Waters, Eschborn, Ger-
many) using a linear gradient from 2% B to 40% B in 3.5 minutes, from 40% B to 80% B in 1.5
minutes, and to 100% B in 0.1 min at 30 μL/min.
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To determine the content of glycerophospholipids, hexoses and acylcarnitines, 50 μL of the
metabolite extract were diluted with 450 μL methanol. Five μL of this dilution were analyzed
in the mass spectrometer by direct infusion using the acquisition parameters as given by the
manufacturer’s manual. Two injections were done to acquire data in positive and negative
mode separately.
Quality control
Technical quality control steps were undertaken before statistical analyses. Individual analyti-
cal batches were normalized to at least 3 replicates of the identical plasma quality control pro-
vided by the kit manufacturer to account for plate-to-plate variability. All metabolites that
exhibited concentration values below limit of detection (as defined by the analytical specifica-
tions) in more than 50% of the measurements were omitted from the dataset (S1 Table).
Statistical analyses
To compare demographic characteristics of the two groups, one-way ANOVA and chi-squared
tests were performed. After quality control 153 metabolites remained available for statistical
analyses (S1 Table). Additionally, various derivative variables were created based on the
metabolite levels (n = 57; S2 Table). To evaluate potential different mean levels of the metabo-
lites between cases and controls non-parametric wilcoxon signed-rank tests designed for
matched samples in case of non-normally distributed data were performed for each variable
(S3 Table). Due to the large number of variables to be evaluated, we used a sparse partial least
squares discriminant analysis (sPLSda) to perform variable selection while taking into account
the correlations between the variables. This approach aims at combining variable selection and
dimension reduction in a one-step procedure.[20] We considered one latent dimension since
we are predicting a univariate binary outcome and to facilitate interpretation of the model.[20]
The optimal tuning parameters (i.e., number of selected predictors) were estimated using a
leave one out cross-validation strategy. Thereafter, a logistic regression was performed on the
selected predictors resulting from the sPLSda to reduce the bias induced by shrinkage.[21] We
performed these analyses on the entire dataset (including the created variables) and on the
crude metabolites only. The discriminative accuracy of each model (resulting from the entire
dataset and from the crude metabolites, respectively) was evaluated using receiver operating
characteristic (ROC) curves and calculation of their corresponding area under the curve
(AUC). Statistical tests were performed using R statistical software (R Core Team (2016). R: A
language and environment for statistical computing. R Foundation for Statistical Computing,
Vienna, Austria. URL https://www.R-project.org/). We used the cran R package “mixOmics”
to train and to test the sPLSda.
Results
Serum samples of 72 cases and 72 control individuals were selected for metabolomic analyses.
Demographic characteristics and other potential confounding factors in our cohort are pro-
vided in Table 1. No significant differences between the groups were detected for sex, age,
smoking status, BMI, diabetic status, diet, complement activation levels and number of CFH
rs1061170 and ARMS2 rs10490924 risk alleles.
Next, we performed sPLSda to select the most predictive variables from our dataset, includ-
ing all 153 measured metabolites and 57 derivative variables. This approach selected four rele-
vant predictors for non-advanced AMD: glutamine, glutamate:glutamine ratio, glutaminolysis,
and phosphatidylcholine diacyl C28:1 (PC aa C28.1) (Table 2; Fig 1). Two of these predictors
are derivative variables that were created from measured metabolite levels, which both
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involved glutamine: the rate of glutaminolysis was expressed by the ratio of the sum of the
potential glutamine conversion products (aspartate, alanine, glutamate) to glutamine (Fig 2),
and another measure of glutamine metabolism was defined as the ratio between glutamine
and glutamate (Glu:Gln ratio).
The distributions of these variables in non-advanced AMD cases and control individuals
are illustrated in Fig 1. A higher mean glutamine level was detected in non-advanced AMD
cases (746.33 μM) compared to controls (695.0 μM). The mean rate of glutaminolysis and the
Glu:Gln ratio were reduced in non-advanced AMD cases (0.73 and 0.08, respectively) com-
pared to controls (0.80 and 0.10, respectively). Besides glutamine levels, mean levels of the
metabolites used to create these custom metabolic indicators were not significantly different






Sex Male 26 (36.1%) 28 (38.9%)
Female 46 (63.9%) 44 (61.1%) 0.73
Age (mean years ±SD) 72.65±7.30 70.64±5.27 0.06
Smoking status Never 34 (47.2%) 37 (51.4%)
Past 38 (52.8%) 35 (48.6%)
Current 0 (0%) 0 (0%) 0.62
BMI (kg/m2) <20 3 (4.2%) 3 (4.2%)
20–25 35 (48.6%) 29 (40.3%)
25–30 28 (38.9%) 33 (45.8%)
>30 6 (8.3%) 7 (9.7%) 0.79
Diabetes Mellitus� Absent 64 (90.1%) 64 (91.4%)
Present 7 (9.9%) 6 (8.6%) 0.79
Diet Regular diet 65 (94.2%) 66 (95.7%)
Vegetarian diet�� 4 (5.8%) 3 (4.3%) 0.70
Complement activation (mean±SD���) C3d/C3 ratio 1.54±0.40 1.47±0.44 0.37
CFH, rs1061170 (C) MAF 44.4 45.1 0.93
ARMS2, rs10490924 (T) MAF 34.7 32.6 0.74
�Self-reported diagnosis
��Vegetarian diet when participant indicated to (almost) never eat fish and red meat
���For the purpose of analyses data was transformed to the natural logarithm
Abbreviations: SD, standard deviation; BMI, body mass index; MAF, minor allele frequency.
https://doi.org/10.1371/journal.pone.0218457.t001
Table 2. Metabolite predictors for non-advanced AMD from sPLSda.
Estimate (β)� Odds ratio��
Glutamine (μM) 0.0037 1.004
Glu:Gln ratio -2.79 0.061
Glutaminolysis -1.73 0.177
PC.aa.C28.1 (μM) 0.62 1.858
�The estimate associated to a predictor represents the change in the log odds per unit change in this predictor if all
other predictors are held constant.
�� The odds ratio represents the odds to be a case given a particular exposure, compared to the odds of being a case in
the absence of that exposure.
https://doi.org/10.1371/journal.pone.0218457.t002
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between cases and controls, although glutamate levels were slightly higher in controls
(S3 Table). The mean level of phosphatidylcholine diacyl C28:1 was elevated in non-advanced
AMD cases (3.35 μM) compared to controls (3.04 μM).
When performing sPLSda on the measured metabolites only (excluding the derivative vari-
ables), glutamine levels were the most predictive for non-advanced AMD (OR 1.005).
The ability to discriminate between cases and controls based on the predictors resulting
from sPLSda of both the entire dataset (including derivative variables) and crude dataset
(excluding derivative variables), respectively, was evaluated using ROC curves and calculation
of the corresponding area under the curves (Fig 3). The model resulting from sPLSda on the
entire dataset (including glutamine, Glu:Gln ratio, glutaminolysis, and PC.aa.C28.1) showed
superior performance (AUC of 0.71, 95% CI: 0.62–0.79) compared to the model including glu-
tamine only as predictor (AUC of 0.66, 95% CI: 0.57–0.75).
Fig 1. Boxplots of the four metabolite predictors for non-advanced AMD from sPLSda. All metabolites were measured in μM.
Glutaminolysis is measured as (cAla+cAsp+cGlu)/cGln.
https://doi.org/10.1371/journal.pone.0218457.g001
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Discussion
In the present study, we investigated potential differences of the metabolome between non-
advanced AMD patients and control individuals using a targeted metabolomics approach.
Four variables were identified by sPLSda as the most predictive features to discriminate
between non-advanced AMD patients and control individuals, including glutamine, gluta-
mine-related variables and a glycerophospholipid (PC aa C28.1). These results are in line with
previous studies describing metabolic differences between AMD patients and controls.[12, 13,
15] Of particular interest is the slightly increased glutamine level in AMD patients, which
Fig 2. Metabolic conversion of glutamine. Glutaminolysis, the metabolic conversion of glutamine to glutamate, aspartate and alanine, represents an
alternative pathway to supply the mitochondrial citric acid cycle with a surplus of α-ketoglutarate. As this pathway is preferentially used by proliferating
tissue, glutaminolysis measured as (cAla+cAsp+cGlu)/cGln is increased in tumor tissue.[22] Metabolites determined in this study are marked in grey.
https://doi.org/10.1371/journal.pone.0218457.g002
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independently corroborates a recent report demonstrating an elevated glutamine level in
early AMD using a different metabolomics technique.[12] Also, other measures of glutamine
metabolism in our study were indicative of a possible association between glutamine and
AMD. In AMD patients, both glutaminolysis (the ratio of glutamate, aspartate and alanine
to glutamine) as well as the Glu:Gln ratio were decreased, although these effects were driven
mainly by elevated levels of glutamine. Glutamine is a nonessential amino acid necessary to
Fig 3. Receiver operating characteristic curves of the logistic regression models obtained from the entire dataset including derivative variables (black curve) and
from crude dataset (blue curve).
https://doi.org/10.1371/journal.pone.0218457.g003
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sustain immune competence,[23] and immunological processes are at the heart of AMD
pathology.[24, 25] It remains to be investigated whether increased glutamine in serum is a
physiological response to a higher demand from the immune system or a result of increased
protein catabolism, decreased clearance of glutamine, increased dietary intake of glutamine, or
other mechanisms. Additionally, one might argue that the change in plasma glutamine levels
might not reflect glutamine changes in RPE or retina, as the glutamine/glutamate system in
the central nervous system (CNS) is characterized by its local, partly autonomous regulation.
There is evidence that glutamate could not readily cross the blood-brain barrier[26], this impli-
cates that the glutamate concentration in the brain is independent from changes of plasma glu-
tamate. However, there is also evidence that the glutamate/glutamine ratio in systemic body
fluids could be explicitly affected by alterations of the CNS metabolism, e.g. in neuropathologi-
cal disorders. For instance, it has been reported repeatedly that autism induces significant
changes in the Glu/Gln ratio in serum[27]. Hence blood glutamate scavenging has been pro-
posed as a treatment option to support neuroprotection in general[28]. With regard to the
above, and the metabolic changes of glutamine reported by another metabolomic study[12]
we are strongly encouraged to propose a significant influence of the retinal tissue on systemic
metabolism.
The observed association between a glycerophospholipid (PC aa C28.1) and non-advanced
AMD is interesting because alterations in concentrations of these species have been implicated
in a variety of metabolic diseases and pathomechanisms.[29–31] Glycerophospholipids and
sphingomyelin are constituents of cell membranes and myelin sheaths, and phosphatidylcho-
lines are the main constituents of lipoproteins,[32] which have been described to be relevant
for AMD pathology.[33, 34] Although literature is not entirely consistent, multiple studies
have associated higher high-density lipoprotein cholesterol levels with increased risk of AMD.
[8, 25, 34–37] Furthermore, it is conceivable that not only levels of lipoprotein classes, but also
their molecular composition in terms of glycerophospholipid species could be potential bio-
markers for AMD development, as has been reported for other conditions, such as arterial
hypertension.[38] Therefore in-depth lipidomics studies that cover a wider range of lipopro-
tein subclasses and their molecular constituents are required to corroborate our findings and
to further explore the relationship between lipids, lipoprotein dynamics and AMD pathology.
It must be noted that the effect sizes of the identified AMD-associated metabolites are
small, consistent with slightly altered metabolic profiles of AMD patients compared to con-
trols. Due to the limited sample size of the current study, we might have been unable to detect
smaller associations and therefore larger studies are warranted. A strength of our study is that
the study groups were carefully selected and matched on potential confounders including age,
sex, smoking status and BMI. Due to this strict patient stratification, differences in metabolites
likely reflect true differences in metabolic profiles between AMD cases and controls. Addition-
ally, our study included patients with non-advanced AMD only, which allows for the identifi-
cation of potentially relevant biomarkers already in an early stage of the disease.
Of note, the samples used for this study were collected at time of enrolment in EUGENDA
and were not specifically collected for the current study. Because of possible influences of diet
on the metabolome, the use of non-fasting samples in this study might not be ideal. However,
although the reproducibility of metabolite levels over time was previously reported to be lower
using non-fasting samples compared to fasting samples, in general the reliability of metabolites
was not significantly different when comparing fasting versus non-fasting samples.[39]
In summary, the findings of this study indicate that metabolomics is a suitable method for
the discovery of biomarkers in AMD. Using a targeted approach, several metabolites were
identified as candidate biomarkers for AMD with glutamine being the most promising, which
may serve as potential targets for future interventions. Larger metabolomic studies are needed
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to further elucidate the metabolic profile of AMD patients. Additionally, untargeted metabolo-
mic studies could provide novel biomarkers in yet unknown AMD pathways and expand our
insights in AMD pathophysiology.
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